Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
+0.05 (0.48%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.34 - 10.90
52 week 7.33 - 13.70
Open 10.45
Vol / Avg. 167,575.00/306,273.00
Mkt cap 260.55M
P/E     -
Div/yield     -
EPS -2.77
Shares 24.81M
Beta 1.75
Inst. own 89%
Mar 8, 2017
Q4 2016 Zogenix Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -214.83% -238.08%
Operating margin -212.23% -251.94%
EBITD margin - -217.86%
Return on average assets -38.85% -25.57%
Return on average equity -72.08% -45.26%
Employees 67 -
CDP Score - -


5858 Horton St Ste 455
EMERYVILLE, CA 94608-2072
United States - Map
+1-510-5508300 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company's areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Gail M. Farfel Ph.D. Executive Vice President, Chief Development Officer
Age: 51
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Thierry J P Darcis Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Roger L. Hawley Director
Age: 62
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 52
Bio & Compensation  - Reuters
Mark C. Wiggins Independent Director
Age: 59
Bio & Compensation  - Reuters